These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23629724)

  • 21. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
    Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
    Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?
    Pagano L; Valentini CG; Fianchi L; Caira M
    J Chemother; 2011 Feb; 23(1):5-8. PubMed ID: 21482486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole.
    Jacobs F; Selleslag D; Aoun M; Sonet A; Gadisseur A
    Eur J Clin Microbiol Infect Dis; 2012 Jun; 31(6):1173-9. PubMed ID: 21971820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan.
    Koh H; Hino M; Ohta K; Iino M; Urase F; Yamaguchi M; Yamanouchi J; Usui N; Yoshida M; Tanimoto M; Ohyashiki K; Urabe A; Tamura K; Kanamaru A; Masaoka T
    J Infect Chemother; 2013 Dec; 19(6):1126-34. PubMed ID: 23813092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan.
    Saito T; Fujiuchi S; Tao Y; Sasaki Y; Ogawa K; Suzuki K; Tada A; Kuba M; Kato T; Kawabata M; Kurashima A; Sakatani M;
    Infection; 2012 Dec; 40(6):661-7. PubMed ID: 22956473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
    Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
    N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
    Pascual A; Nieth V; Calandra T; Bille J; Bolay S; Decosterd LA; Buclin T; Majcherczyk PA; Sanglard D; Marchetti O
    Antimicrob Agents Chemother; 2007 Jan; 51(1):137-43. PubMed ID: 17088483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Voriconazole plasma monitoring.
    Pasqualotto AC; Shah M; Wynn R; Denning DW
    Arch Dis Child; 2008 Jul; 93(7):578-81. PubMed ID: 18252755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.
    Denning DW; Griffiths CE
    Clin Exp Dermatol; 2001 Nov; 26(8):648-53. PubMed ID: 11722447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.
    Vanstraelen K; Wauters J; Vercammen I; de Loor H; Maertens J; Lagrou K; Annaert P; Spriet I
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6782-9. PubMed ID: 25182655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
    Dolton MJ; Ray JE; Chen SC; Ng K; Pont LG; McLachlan AJ
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4793-9. PubMed ID: 22751544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
    Sambatakou H; Dupont B; Lode H; Denning DW
    Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors associated with insufficient and potentially toxic voriconazole plasma concentrations: an observational study.
    Wei X; Zhao M; Fu P; Xiao X
    J Chemother; 2019; 31(7-8):401-407. PubMed ID: 31359851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.
    Guinea J; Escribano P; Marcos-Zambrano LJ; Peláez T; Kestler M; Muñoz P; Vena A; López-Fabal F; Bouza E
    Med Mycol; 2016 May; 54(4):353-60. PubMed ID: 26739190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review.
    Davies-Vorbrodt S; Ito JI; Tegtmeier BR; Dadwal SS; Kriengkauykiat J
    Pharmacotherapy; 2013 Jan; 33(1):22-30. PubMed ID: 23307541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Voriconazole treatment for less-common, emerging, or refractory fungal infections.
    Perfect JR; Marr KA; Walsh TJ; Greenberg RN; DuPont B; de la Torre-Cisneros J; Just-Nübling G; Schlamm HT; Lutsar I; Espinel-Ingroff A; Johnson E
    Clin Infect Dis; 2003 May; 36(9):1122-31. PubMed ID: 12715306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
    Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
    Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.
    Troke PF; Hockey HP; Hope WW
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4782-8. PubMed ID: 21768513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma concentrations of voriconazole in falcons.
    Schmidt V; Demiraj F; Di Somma A; Bailey T; Ungemach FR; Krautwald-Junghanns ME
    Vet Rec; 2007 Aug; 161(8):265-8. PubMed ID: 17720963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.